Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update

Slide: 31 of 40

Additional Possible Adverse Effects

These potentially severe adverse effects are listed by the FDA but are not findings of the CER:

Alendronate, risedronate, and ibandronate are associated with musculoskeletal pain, hypocalcemia, osteonecrosis of the jaw, and severe irritation of the upper gastrointestinal mucosa.

Zoledronic acid is associated with musculoskeletal pain, renal toxicity and failure, and atrial fibrillation.

Denosumab is associated with hypocalcemia and osteonecrosis of the jaw.

Teriparatide is associated with an increased risk of bone cancer.

Symptoms of vitamin D toxicity include nausea, vomiting, anorexia, polyuria, constipation, weakness, and weight loss. Excessive vitamin D causes hypercalcemia, which can cause dementia, memory loss, and arrhythmias, as well as irreversible kidney damage and renal failure.